Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Cancer Prevention02:59

Cancer Prevention

6.5K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cancer02:18

Cancer

51.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.4K
Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial.

Obstetrical & gynecological survey·2025
Same author

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial.

Obstetrical & gynecological survey·2025
Same author

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.

The Lancet. Oncology·2025
Same author

INTERLACE: not a new standard for cervical cancer chemoradiation - Authors' reply.

Lancet (London, England)·2025
Same author

A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

An Expanded Access Protocol of RNS60 in Amyotrophic Lateral Sclerosis.

Muscle & nerve·2025

Related Experiment Video

Updated: Apr 25, 2026

Generation and Genetic Manipulation of Human Cervical Organoids
09:41

Generation and Genetic Manipulation of Human Cervical Organoids

Published on: March 10, 2026

117

Promising new developments in cervical cancer.

Mary McCormack, Francesca Lake

    Future Oncology (London, England)
    |August 23, 2014
    PubMed
    Summary

    Dr. Mary McCormack is a clinical oncologist specializing in gynecological and breast cancers, offering chemotherapy and radiotherapy. She actively contributes to national and international clinical trials for gynecologic cancers.

    Area of Science:

    • Oncology
    • Gynecologic Oncology
    • Breast Oncology

    Background:

    • Dr. McCormack is a consultant clinical oncologist at University College London Hospitals.
    • She specializes in chemotherapy and radiotherapy for gynecological and breast cancers.

    Discussion:

    • She is a member of the National Cancer Research Institute Gynecological Clinical Studies Group and the Gynecologic Cancer InterGroup.
    • Dr. McCormack is a significant contributor to national and international clinical trials.

    Key Insights:

    • Her expertise lies in the treatment of gynecological and breast malignancies.
    • She is involved in advancing cancer research through clinical trials.

    Outlook:

    • Dr. McCormack is a medical advisor to Jo's Trust, a UK-based charity focused on women's health.
    Keywords:
    INTERLACEbevacizumabcervical cancerrelapsed diseaseresearch

    More Related Videos

    Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
    06:57

    Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

    Published on: June 14, 2019

    10.5K
    Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
    08:09

    Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection

    Published on: July 25, 2017

    12.1K

    Related Experiment Videos

    Last Updated: Apr 25, 2026

    Generation and Genetic Manipulation of Human Cervical Organoids
    09:41

    Generation and Genetic Manipulation of Human Cervical Organoids

    Published on: March 10, 2026

    117
    Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
    06:57

    Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

    Published on: June 14, 2019

    10.5K
    Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
    08:09

    Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection

    Published on: July 25, 2017

    12.1K
  • She is a founding member of the Debbie Fund, supporting cervical cancer research.